MYC and osteosarcoma: This study revealed for the first time that c-Myc inhibition can enhance T cell infiltration and activation in osteosarcoma in multiple ways, thus showing great potential for establishing c-Myc inhibitor and ICB coadministration as a novel therapeutic regimen for patients with osteosarcoma.